vs
Avantor, Inc.（AVTR）とEntergy（ETR）の財務データ比較。上の社名をクリックして会社を切り替えられます
Entergyの直近四半期売上が大きい（$3.0B vs $1.7B、Avantor, Inc.の約1.8倍）。Entergyの純利益率が高く（8.1% vs 3.1%、差は5.0%）。Entergyの前年同期比売上増加率が高い（7.9% vs -1.4%）。Avantor, Inc.の直近四半期フリーキャッシュフローが多い（$117.2M vs $-909.7M）。過去8四半期でEntergyの売上複合成長率が高い（2.9% vs -0.5%）
アバンター社は米国ペンシルベニア州ラドノーに本社を置くバイオテクノロジー・化学・医薬品企業です。1904年にJ.T.ベイカーとして創業し2010年に現社名に変更、2019年にNY証券取引所に上場し、証券コードは「AVTR」で、世界中のライフサイエンス分野の顧客に製品を提供しています。
Entergy社はアメリカ合衆国のエネルギー企業で、電力生産と小売供給事業を営み、本部はルイジアナ州ニューオーリンズに位置する。アーカンソー州、ルイジアナ州、ミシシッピ州、テキサス州の300万顧客に電力を供給し、発電容量約2万4000メガワット、年間売上高110億米ドル、従業員数は1万2000人を超える。
AVTR vs ETR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $1.7B | $3.0B |
| 純利益 | $52.4M | $240.5M |
| 粗利率 | 31.5% | — |
| 営業利益率 | 7.6% | 18.4% |
| 純利益率 | 3.1% | 8.1% |
| 売上前年比 | -1.4% | 7.9% |
| 純利益前年比 | -89.5% | -16.2% |
| EPS（希薄化後） | $0.08 | $0.51 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $1.7B | $3.0B | ||
| Q3 25 | $1.6B | $3.8B | ||
| Q2 25 | $1.7B | $3.3B | ||
| Q1 25 | $1.6B | $2.8B | ||
| Q4 24 | $1.7B | $2.7B | ||
| Q3 24 | $1.7B | $3.4B | ||
| Q2 24 | $1.7B | $3.0B | ||
| Q1 24 | $1.7B | $2.8B |
| Q4 25 | $52.4M | $240.5M | ||
| Q3 25 | $-711.8M | $698.4M | ||
| Q2 25 | $64.7M | $472.0M | ||
| Q1 25 | $64.5M | $362.4M | ||
| Q4 24 | $500.4M | $287.2M | ||
| Q3 24 | $57.8M | $645.8M | ||
| Q2 24 | $92.9M | $51.7M | ||
| Q1 24 | $60.4M | $76.5M |
| Q4 25 | 31.5% | — | ||
| Q3 25 | 32.4% | — | ||
| Q2 25 | 32.9% | — | ||
| Q1 25 | 33.8% | — | ||
| Q4 24 | 33.4% | — | ||
| Q3 24 | 32.9% | — | ||
| Q2 24 | 34.1% | — | ||
| Q1 24 | 34.0% | — |
| Q4 25 | 7.6% | 18.4% | ||
| Q3 25 | -40.0% | 29.4% | ||
| Q2 25 | 7.7% | 25.2% | ||
| Q1 25 | 9.3% | 24.6% | ||
| Q4 24 | 37.8% | 24.4% | ||
| Q3 24 | 7.3% | 33.2% | ||
| Q2 24 | 10.3% | 20.9% | ||
| Q1 24 | 8.7% | 8.5% |
| Q4 25 | 3.1% | 8.1% | ||
| Q3 25 | -43.8% | 18.3% | ||
| Q2 25 | 3.8% | 14.2% | ||
| Q1 25 | 4.1% | 12.7% | ||
| Q4 24 | 29.7% | 10.5% | ||
| Q3 24 | 3.4% | 19.1% | ||
| Q2 24 | 5.5% | 1.8% | ||
| Q1 24 | 3.6% | 2.7% |
| Q4 25 | $0.08 | $0.51 | ||
| Q3 25 | $-1.04 | $1.53 | ||
| Q2 25 | $0.09 | $1.05 | ||
| Q1 25 | $0.09 | $0.82 | ||
| Q4 24 | $0.73 | $0.66 | ||
| Q3 24 | $0.08 | $1.50 | ||
| Q2 24 | $0.14 | $0.11 | ||
| Q1 24 | $0.09 | $0.18 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $365.4M | $1.9B |
| 総負債低いほど良い | $3.9B | $30.3B |
| 株主資本純資産 | $5.6B | $16.9B |
| 総資産 | $11.8B | $71.9B |
| 負債/資本比率低いほどレバレッジが低い | 0.71× | 1.79× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $365.4M | $1.9B | ||
| Q3 25 | $251.9M | $1.5B | ||
| Q2 25 | $449.4M | $1.2B | ||
| Q1 25 | $315.7M | $1.5B | ||
| Q4 24 | $261.9M | $859.7M | ||
| Q3 24 | $285.3M | $1.4B | ||
| Q2 24 | $272.6M | $1.4B | ||
| Q1 24 | $234.9M | $1.3B |
| Q4 25 | $3.9B | $30.3B | ||
| Q3 25 | $3.9B | $29.0B | ||
| Q2 25 | $4.2B | $29.9B | ||
| Q1 25 | $4.1B | $29.6B | ||
| Q4 24 | $4.1B | $28.0B | ||
| Q3 24 | $4.9B | $27.9B | ||
| Q2 24 | $5.1B | $27.8B | ||
| Q1 24 | $5.3B | $26.5B |
| Q4 25 | $5.6B | $16.9B | ||
| Q3 25 | $5.6B | $16.7B | ||
| Q2 25 | $6.3B | $16.2B | ||
| Q1 25 | $6.1B | $15.2B | ||
| Q4 24 | $6.0B | $15.1B | ||
| Q3 24 | $5.6B | $15.0B | ||
| Q2 24 | $5.4B | $14.6B | ||
| Q1 24 | $5.3B | $14.5B |
| Q4 25 | $11.8B | $71.9B | ||
| Q3 25 | $11.7B | $69.8B | ||
| Q2 25 | $12.8B | $68.4B | ||
| Q1 25 | $12.3B | $66.6B | ||
| Q4 24 | $12.1B | $64.8B | ||
| Q3 24 | $12.8B | $64.5B | ||
| Q2 24 | $12.7B | $62.8B | ||
| Q1 24 | $12.8B | $61.6B |
| Q4 25 | 0.71× | 1.79× | ||
| Q3 25 | 0.69× | 1.74× | ||
| Q2 25 | 0.67× | 1.85× | ||
| Q1 25 | 0.67× | 1.95× | ||
| Q4 24 | 0.68× | 1.86× | ||
| Q3 24 | 0.89× | 1.85× | ||
| Q2 24 | 0.94× | 1.91× | ||
| Q1 24 | 1.00× | 1.83× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $152.7M | $1.2B |
| フリーキャッシュフロー営業CF - 設備投資 | $117.2M | $-909.7M |
| FCFマージンFCF / 売上 | 7.0% | -30.7% |
| 設備投資強度設備投資 / 売上 | 2.1% | 71.9% |
| キャッシュ転換率営業CF / 純利益 | 2.91× | 5.06× |
| 直近12ヶ月FCF直近4四半期 | $495.0M | $-2.5B |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $152.7M | $1.2B | ||
| Q3 25 | $207.4M | $2.1B | ||
| Q2 25 | $154.4M | $1.3B | ||
| Q1 25 | $109.3M | $536.2M | ||
| Q4 24 | $173.3M | $1.4B | ||
| Q3 24 | $244.8M | $1.6B | ||
| Q2 24 | $281.1M | $1.0B | ||
| Q1 24 | $141.6M | $521.1M |
| Q4 25 | $117.2M | $-909.7M | ||
| Q3 25 | $171.7M | $246.0M | ||
| Q2 25 | $124.8M | $-746.6M | ||
| Q1 25 | $81.3M | $-1.1B | ||
| Q4 24 | $145.8M | $-193.8M | ||
| Q3 24 | $204.0M | $421.8M | ||
| Q2 24 | $235.3M | $-137.8M | ||
| Q1 24 | $106.9M | $-440.1M |
| Q4 25 | 7.0% | -30.7% | ||
| Q3 25 | 10.6% | 6.5% | ||
| Q2 25 | 7.4% | -22.4% | ||
| Q1 25 | 5.1% | -39.5% | ||
| Q4 24 | 8.6% | -7.1% | ||
| Q3 24 | 11.9% | 12.4% | ||
| Q2 24 | 13.8% | -4.7% | ||
| Q1 24 | 6.4% | -15.7% |
| Q4 25 | 2.1% | 71.9% | ||
| Q3 25 | 2.2% | 49.5% | ||
| Q2 25 | 1.8% | 60.3% | ||
| Q1 25 | 1.8% | 58.3% | ||
| Q4 24 | 1.6% | 57.4% | ||
| Q3 24 | 2.4% | 33.7% | ||
| Q2 24 | 2.7% | 39.4% | ||
| Q1 24 | 2.1% | 34.4% |
| Q4 25 | 2.91× | 5.06× | ||
| Q3 25 | — | 3.06× | ||
| Q2 25 | 2.39× | 2.67× | ||
| Q1 25 | 1.69× | 1.48× | ||
| Q4 24 | 0.35× | 4.80× | ||
| Q3 24 | 4.24× | 2.42× | ||
| Q2 24 | 3.03× | 19.82× | ||
| Q1 24 | 2.34× | 6.81× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AVTR
| Laboratory Solutions Segment | $1.1B | 67% |
| Bioscience Production Segment | $547.5M | 33% |
ETR
| Electricity Us Regulated | $2.9B | 100% |
| Other | $13.7M | 0% |
